(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
23 June 2005 (23.06.2005)

PCT

(10) International Publication Number
WO 2005/056554 A3

(51) International Patent Classification[7]: C07D 487/04, A61K 31/435, A61P 31/04, 31/10, A61K 31/55

(21) International Application Number: PCT/US2004/040352

(22) International Filing Date: 1 December 2004 (01.12.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10/895,431 2 December 2003 (02.12.2003) US

(71) Applicant *(for all designated States except US)*: **X-CEPTOR THERAPEUTICS, INC.** [US/US]; 4757 Nexus Center Drive, San Diego, California 92121 (US).

(72) Inventors; and


(75) Inventors/Applicants *(for US only)*: **BUSCH, Brett** [US/US]; 7523 Mona Lane, San Diego, California 92130 (US). **FLATT, Brenton, T.** [US/US]; 12721 Pedriza Drive, Poway, California 92064 (US). **GU, Xiao-Hui** [CN/US]; 7699 Palmilla Drive, #3408, San Diego, California 92122-5098 (US). **MARTIN, Richard** [CA/US]; 4293 Cordobes Cove, San Diego, California 92130 (US). **MOHAN, Raju** [US/US]; 3125 Caminito Ricardo, Encinitas, California 92024 (US). **WANG, Tie-Lin** [CN/US]; 7746 Roan Road, San Diego, California 92129 (US). **WU, Jason, H.** [US/US]; 8310 Regents Road, #3B, San Diego, California 92122 (US).


(74) Agents: **ROTH, Carol, J.** et al.; Seed Intellectual Property Law Group PLLC, Suite 6300, 701 Fifth Avenue, Seattle, Washington 98104-7092 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,

[Continued on next page]

(54) Title: AZEPINOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS





(I)

(57) Abstract: Compounds for use in pharmaceutical compositions and methods for modulating the activity of nuclear receptors are provided. In particular, compounds for use in compositions and methods for modulating the farnesoid X receptor, and/or orphan nuclear receptors, are provided.: formula (I) or a pharmaceutically acceptable derivative thereof; wherein: R^1 is $-C(J)OR^{14}$, $-C(J)SR^{14}$ and $-C(J)N(R^{15})R^{16}$, J is O, S or NR^{17}, R^2 is hydrogen, halo or optionally substituted alkyl; R^3 is $-C(O)R^9$, R^4, R^5, R^6 and R^7 and R^8 are as described in the claims.

WO 2005/056554 A3

GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report:
18 August 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.